 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Keytruda (pembrolizumab) / Merck (MSD)
Phase classification, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=450, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P2 --> P1/2
- Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Phase 1 study of anti (Hall A; Poster Bd #: 119) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3869;
P1
The 4-drug combination showed increased clinical efficacy compared with that historically observed for chemotherapy regimens. Further evaluation is needed to confirm the clinical activities observed.
- Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Phase 1 study of anti (Hall A; Poster Bd #: 345) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3153;
P1
All patients had previously received systemic therapy: 24 of 25 (96%) received prior temozolomide and 3 of 25 (12%) received prior glasdegib. MK-0482 + pembro had a manageable AE profile with modest antitumor activity in patients with recurrent inoperable GBM.
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Phase classification, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Mar 12, 2024
P1, N=230, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
MK-0482 + pembro had a manageable AE profile with modest antitumor activity in patients with recurrent inoperable GBM. Phase classification: P1b --> P1
- Keytruda (pembrolizumab) / Merck (MSD)
Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy (Section 48) - Mar 5, 2024 - Abstract #AACR2024AACR_7883;
Phase classification: P1b --> P1 Abstract is embargoed at this time.
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Feb 15, 2024
P2, N=360, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Abstract is embargoed at this time. Trial completion date: Feb 2032 --> Feb 2039 | Trial primary completion date: Feb 2032 --> Feb 2039
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Metastases: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Dec 27, 2023
P2, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Feb 2032 --> Feb 2039 | Trial primary completion date: Feb 2032 --> Feb 2039 Trial completion date: Feb 2032 --> Sep 2025 | Trial primary completion date: Feb 2032 --> Sep 2025
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Combination therapy, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Nov 13, 2023
P2, N=360, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Feb 2032 --> Sep 2025 | Trial primary completion date: Feb 2032 --> Sep 2025 Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Combination therapy, Metastases: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Nov 13, 2023
P2, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1055;
Conclusions Functional spatial profiling of the cancer patient TME following multiplexed intratumoral CIVO microinjection enabled in-depth, safe, and efficient side-by-side evaluation of pembrolizumab alone and in combination with MK-0482 or MK-4830. Further study to determine whether the localized TME responses to CIVO predict the therapeutic benefit of checkpoint inhibitor combinations in different patient subsets is warranted.
- || MK-0482 / Merck (MSD)
Enrollment closed: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov) - Sep 7, 2023
P1b, N=35, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Further study to determine whether the localized TME responses to CIVO predict the therapeutic benefit of checkpoint inhibitor combinations in different patient subsets is warranted. Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Enrollment closed, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - May 25, 2023
P1b, N=230, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov) - May 6, 2023
P1b, N=35, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2025
- || MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Enrollment change: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov) - Jan 5, 2023
P1, N=15, Recruiting, Sponsor: Presage Biosciences
Trial completion date: May 2024 --> Aug 2025 | Trial primary completion date: May 2024 --> Aug 2025 N=24 --> 15
- MK-0482 / Merck (MSD)
Phase 1b Trial of Anti-Immunoglobulin-like Transcript 3 Monoclonal Antibody MK-0482 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia () - Nov 29, 2022 - Abstract #ASH2022ASH_7279;
P1b
Samples for PK analyses will be collected before and after treatment on day 1 of cycles 1-4, 6, 8, and every 4 cycles thereafter. The study is currently ongoing.
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Combination therapy, Metastases: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov) - Nov 3, 2022
P2, N=135, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
The study is currently ongoing. Recruiting --> Active, not recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Nov 2, 2022
P2, N=360, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting N=270 --> 360
- || Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Jul 12, 2022
P1b, N=230, Recruiting, Sponsor: Merck Sharp & Dohme LLC
N=270 --> 360 Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
- Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1579;
P1b
MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Mar 17, 2022
P2, N=120, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts. N=60 --> 120
- || MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Enrollment change: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov) - Feb 22, 2022
P1, N=24, Recruiting, Sponsor: Presage Biosciences
N=60 --> 120 N=36 --> 24
- || Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Feb 16, 2022
P1b, N=230, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=36 --> 24 Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
- | MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov) - Jan 25, 2022
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024 Trial completion date: Sep 2025 --> May 2024 | Trial primary completion date: Sep 2025 --> May 2024
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Oct 27, 2021
P2, N=270, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Sep 2025 --> May 2024 | Trial primary completion date: Sep 2025 --> May 2024 N=180 --> 270
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov) - Oct 22, 2021
P2, N=135, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=180 --> 270 Active, not recruiting --> Recruiting
- || MK-0482 / Merck (MSD)
Enrollment open: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov) - Oct 3, 2021
P1b, N=30, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- || MK-0482 / Merck (MSD)
New P1 trial: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (clinicaltrials.gov) - Sep 8, 2021
P1b, N=30, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov) - Jun 15, 2021
P2, N=135, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=90 --> 135
- || MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Enrollment open, Enrollment change, Trial initiation date: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov) - Jun 4, 2021
P1, N=36, Recruiting, Sponsor: Presage Biosciences
N=90 --> 135 Not yet recruiting --> Recruiting | N=12 --> 36 | Initiation date: Feb 2021 --> Jun 2021
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Combination therapy, Metastases: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov) - May 26, 2021
P2, N=90, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | N=12 --> 36 | Initiation date: Feb 2021 --> Jun 2021 Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Apr 22, 2021
P1b, N=230, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial completion date: Aug 2022 --> Jun 2024 | Trial primary completion date: Aug 2022 --> Jun 2024
- || Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Enrollment change, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Mar 21, 2021
P1b, N=230, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Aug 2022 --> Jun 2024 | Trial primary completion date: Aug 2022 --> Jun 2024 N=85 --> 230
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Mar 3, 2021
P2, N=180, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=85 --> 230 N=90 --> 180
- || MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov) - Feb 11, 2021
P1, N=12, Not yet recruiting, Sponsor: Presage Biosciences
N=90 --> 180 Trial completion date: Dec 2030 --> Dec 2031 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: Dec 2030 --> Dec 2031
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Jan 19, 2021
P2, N=60, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Dec 2030 --> Dec 2031 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: Dec 2030 --> Dec 2031 Suspended --> Recruiting
- || MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
New P1 trial, PD(L)-1 Biomarker: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies (clinicaltrials.gov) - Sep 8, 2020
P1, N=12, Not yet recruiting, Sponsor: Presage Biosciences
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Jul 14, 2020
P1b, N=85, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Suspended --> Recruiting Trial completion date: May 2021 --> Jul 2022 | Trial primary completion date: May 2021 --> Jul 2022
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov) - Jun 18, 2020
P2, N=90, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: May 2021 --> Jul 2022 | Trial primary completion date: May 2021 --> Jul 2022 N=45 --> 90
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial initiation date, Combination therapy, Metastases: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Jun 15, 2020
P2, N=60, Suspended, Sponsor: Merck Sharp & Dohme Corp.
N=45 --> 90 Initiation date: May 2020 --> Nov 2020
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - May 22, 2020
P1b, N=85, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: May 2020 --> Nov 2020 Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial suspension, Combination therapy, Metastases: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Apr 30, 2020
P2, N=60, Suspended, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jan 2021 --> May 2021 | Trial primary completion date: Jan 2021 --> May 2021 Not yet recruiting --> Suspended
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Mar 17, 2020
P1b, N=85, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Suspended Trial completion date: May 2021 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Jan 13, 2020
P2, N=90, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: May 2021 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov) - Jan 13, 2020
P2, N=45, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Combination therapy, Metastases: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Nov 15, 2019
P2, N=90, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Combination therapy, Metastases: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Nov 15, 2019
P2, N=60, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Combination therapy, Metastases: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov) - Nov 15, 2019
P2, N=45, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Jul 22, 2019
P1b, N=85, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial completion date: Oct 2021 --> May 2021 | Trial primary completion date: Oct 2021 --> May 2021
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Enrollment open, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Jun 25, 2019
P1b, N=85, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Oct 2021 --> May 2021 | Trial primary completion date: Oct 2021 --> May 2021 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
New P1 trial, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Apr 17, 2019
P1b, N=85, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.